Notizie e Video - EVOTEC SEINH O.N. - Pagina 2

HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024. The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing priority reset and the strategic review process. The conference call will be held in English. Webcast details Date: Wednesday, 06...

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec and Bristol Myers Squibb expand proteomics partnership 23.10.2024 / 07:29 CET/CEST The issuer is solely responsible for the content of this announcement. Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value Hamburg, Germany, 23 October 2024:...

EQS-News: Evotec SE / Schlagwort(e): Sonstiges Evotec und Bristol Myers Squibb erweitern Proteomics-Partnerschaft 23.10.2024 / 07:29 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Wichtige wissenschaftliche Erfolge treiben den Ausbau der Pipeline von Molecular Glue Degraders in Bereichen außerhalb der Onkologie voran Evotec erhält eine Zahlung von 50 Mio. US$ von Bristol Myers Squibb; potenzielle programmbezogene Meilensteinzahlungen tragen zum Wert der...

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value HAMBURG, GERMANY / ACCESSWIRE / October 23, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced progress within the Company's strategic partnership with Bristol Myers Squibb relating to...

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies 26.09.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies Hamburg, Germany, 26 September 2024: Evotec SE (Frankfurt Stock Exchange: EVT,...

EQS-News: Evotec SE / Schlagwort(e): Sonstiges Evotec und Novo Nordisk gehen Technologiepartnerschaft für Zelltherapien der nächsten Generation ein 26.09.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Novo Nordisk stellt finanzielle Mittel für die Technologieentwicklung bei Evotec zur Verfügung, um die klinische und kommerzielle Herstellung von stammzellbasierten Therapien zu unterstützen Hamburg, 26. September 2024: Evotec SE...

Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy. Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support...

EQS-News: Evotec SE / Schlagwort(e): Sonstiges Just – Evotec Biologics eröffnet hochmoderne Biologika-Anlage - J.POD® Toulouse, France (EU) 20.09.2024 / 15:29 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. J.POD ® Toulouse, France (EU) bringt disruptive, skalierbare, kontinuierliche Biologika-Herstellungstechnologie in die Region Just – Evotec Biologics J.POD ® -Technologie bietet einen Paradigmenwechsel in der Bioproduktion mit kosteneffizienten...

EQS-News: Evotec SE / Key word(s): Miscellaneous Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU) 20.09.2024 / 15:29 CET/CEST The issuer is solely responsible for the content of this announcement. J.POD ® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region Just – Evotec Biologics’ J.POD ® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical...

J.POD ® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region Just - Evotec Biologics' J.POD ® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions HAMBURG, GERMANY and TOULOUSE, FRANCE / ACCESSWIRE / September 20, 2024 / Just - Evotec Biologics, the biologics segment of Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO), today...

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec announces change in Management Board 03.09.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Dr Matthias Evers steps down as Chief Business Officer effective 01 October 2024 Distribution of responsibilities across other Management Board functions Hamburg, Germany, 03 September 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its...

EQS-News: Evotec SE / Schlagwort(e): Sonstiges Evotec gibt Veränderung im Vorstand bekannt 03.09.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Dr. Matthias Evers tritt mit Wirkung zum 01. Oktober 2024 als Chief Business Officer zurück Verantwortlichkeiten werden auf andere Vorstandsressorts verteilt Hamburg, 03. September 2024: Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) gab heute bekannt,...

Dr Matthias Evers steps down as Chief Business Officer effective 01 October 2024 Distribution of responsibilities across other Management Board functions HAMBURG, GERMANY / ACCESSWIRE / September 3, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced that its Chief Business Officer, Dr Matthias Evers, has decided to step down to pursue opportunities outside of Evotec. He will leave the Company effective 01 October 2024. Matthias was...

EQS-News: Evotec SE / Key word(s): Half Year Results Evotec SE reports H1 2024 results: Challenging year; priority reset for sustainable profitable growth gaining momentum, building on core strengths 14.08.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery – higher share of integrated long-term deals will improve...

EQS-News: Evotec SE / Schlagwort(e): Halbjahresergebnis Evotec SE gibt Ergebnisse für H1 2024 bekannt: Herausforderndes Jahr; Neuausrichtung für nachhaltiges profitables Wachstum aufbauend auf Kernkompetenzen gewinnt an Dynamik 14.08.2024 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Weicher Markt für Shared R&D Dienstleistungen; Umsatz geht im ersten Halbjahr 2024 im Vergleich zum Vorjahr um 7 % zurück. Anhaltendes Wachstum des...

Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery - higher share of integrated long-term deals will improve revenue contribution beyond 2024 Strong progress of Just - Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity ramp-up for J.POD in Toulouse has been accelerated Challenging market environment and high fixed cost base led to weaker profitability. Priority reset towards...

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb 13.08.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Key scientific achievements drive the expansion of the pipeline of molecular glue degraders Performance-based and programme-based payments of in total US$ 75 m to Evotec Hamburg, Germany, 13 August 2024: Evotec SE (Frankfurt Stock Exchange: EVT,...

EQS-News: Evotec SE / Schlagwort(e): Sonstiges Evotec verkündet starke Fortschritte in strategischer Partnerschaft mit Bristol Myers Squibb im Bereich Protein Degradation 13.08.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Wichtige wissenschaftliche Erfolge treiben die Erweiterung der Pipeline von Molecular Glue Degraders voran Leistungs- und programmabhängige Zahlungen an Evotec in Höhe von insgesamt 75 Mio. US$ Hamburg, 13. August 2024:...

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders Performance-based and programme-based payments of in total US$ 75 m to Evotec HAMBURG, GERMANY / ACCESSWIRE / August 13, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced further strong progress of the Company's strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Performance-based and...

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb 08.08.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research Hamburg, Germany, 08 August 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO)...